Executive Summary
Generated July 30, 2026
AI Labs
SenseTime
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Headquarters
Hong Kong / Shanghai, China
Website
Employees
5,000 (2024, approximate)
Founded
2014
Listing
0020 · Hong Kong Stock Exchange
Market Cap
HKD 58.34B
Revenue (TTM)
HKD 5.01B
Price
HKD1.44 (+2.86%)
Market data as of Jul 29, 2026, 11:25 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
SenseTime is a major Chinese AI company specializing in computer vision, deep learning, and generative AI, regarded as one of China's "Four AI Dragons" and a bellwether for the country's AI commercialization progress. Full-year 2025 revenue reached 5.015 billion yuan (~$728 million), up 32.4%, with generative AI revenue jumping 51% to 3.63 billion yuan — now over 70% of total revenue — while its annual net loss narrowed 58.6% and the company posted its first positive EBITDA and operating cash flow since IPO in H2 2025. Its "1+X" strategy pairs Generative AI and Computer Vision with vertical bets in Smart Auto, Smart Healthcare, Home Robotics, and Smart Retail.
Strategic Connections
- Huawei: SenseTime, like other major Chinese AI companies, depends increasingly on domestic chip alternatives including Huawei's Ascend processors.
- Alibaba: SenseTime, one of China's 'Four AI Dragons,' competes with Alibaba and other major Chinese technology companies building large language models and generative AI platforms.
Strategic Risks
- Has faced US sanctions and export restrictions specifically targeting the company
Future Outlook
- Continued expansion into generative AI applications built on domestic compute infrastructure
Sources
2 sources, 75% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.